European Carotid Surgery Trial 2
| ISRCTN | ISRCTN97744893 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN97744893 |
| Secondary identifying numbers | 11034 |
- Submission date
- 05/07/2012
- Registration date
- 05/07/2012
- Last edited
- 23/04/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English Summary
Background and study aims
Atherosclerotic carotid stenosis is a narrowing of the carotid artery in the neck by fatty deposits. It is an important cause of stroke, and hence disability and premature death. Previous studies have shown that an operation to remove the narrowing, known as carotid endarterectomy (CEA), is more effective than treatment with tablets to prevent stroke. In some patients a treatment called stenting may be as effective as surgery. Stenting involves a wire mesh tube being inserted via an artery in the groin and opened up across the narrowing in the neck. However, drug treatment has improved since the original studies of surgery. We think medical treatment is now so effective that the benefits of removing the narrowing may not justify the risk of surgery or stenting in patients with a lower risk of stroke, such as those who have had no symptoms for some months or never had symptoms from the narrowing. The aim of this study is to determine whether these patients should be managed by drug treatment alone or should still be referred for surgery or stenting.
Who can participate?
Patients over 18 years of age with atherosclerotic carotid stenosis and at a lower risk of stroke.
What does the study involve?
Participants have their medication adjusted to reach the recommended levels for cholesterol and blood pressure, and receive advice about healthy lifestyle. Half of the patients are randomly allocated to have surgery or stenting as soon as possible, and the other half continue on medical treatment alone until such time, if ever, that revascularisation surgery becomes clearly indicated. Participants are seen regularly for several years to check their cholesterol and blood pressure remain on target and to record any surgical complications and the occurrence of strokes or heart attacks.
What are the possible benefits and risks of participating?
The results will be used to help patients and doctors to choose which treatment plan is the safest and most effective. Both surgical endarterectomy and stenting carry a risk of causing a stroke at the time of the treatment. Previous studies showed a risk of stroke or death at the time of surgery or stenting of between 3 and 6 patients in every 100 patients. Treatment is not always successful and the carotid stenosis may recur and require further treatment or the artery may become blocked. A proportion of people treated with optimized medical treatment will also suffer stroke at some time during follow-up despite treatment. Stroke caused by surgery, stenting or occurring during OMT may recover, cause permanent disablement or be fatal. Surgery also has a risk of causing a heart attack. About one in ten patients has cranial nerve palsy (temporary tongue or facial weakness). A haematoma (a solid swelling of clotted blood) may form at the site of incision, which may require removal. Angiography and stenting may also result in bruising or haematoma at the site of injection (usually in the groin) and can cause temporary discomfort or pain in the neck. There is a small risk of allergic reactions to the dye. The drugs used as part of OMT may cause adverse reactions or allergic reactions. The medical treatment that patients in both arms will receive will be carefully monitored and optimised with targets for control of blood pressure and lipid levels and advice on lifestyle. In the revascularisation group the surgeons and interventionists providing this treatment will have to show acceptable complication levels laid down in the protocol before their centre can be enrolled to randomise patients into the study. We have designed the protocol in such a way as to minimise risks to patients in both arms of the study and all patients should benefit from the optimisation and monitoring of their medical treatment.
Where is the study run from?
University College London, UK, University Hospital, Basel, Switzerland, and Amsterdam Medical Centre, The Netherlands.
(updated 10/11/2020, previously: The National Hospital for Neurology and Neurosurgery (UK))
When is the study starting and how long is it expected to run for?
March 2012 to March 2025
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
Ekaterina Biggs
e.allsop@ucl.ac.uk
Contact information
Scientific
Stroke Research Group
Institute of Neurology, University College London
Box 6, The National Hospital
Queen Square
London
WC1N 3BG
United Kingdom
 ORCID ID |
0000-0002-3273-1356 |
|---|---|
| martin.brown@ucl.ac.uk |
Study information
| Study design | Randomised controlled interventional trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | European Carotid Surgery Trial 2 (ECST-2): a randomised controlled trial |
| Study acronym | ECST 2 |
| Study hypothesis | Narrowing of the carotid artery in the neck by fatty deposits is an important cause of stroke, and hence disability and premature death. Previous trials have shown that an operation to remove the narrowing, known as carotid endarterectomy (CEA), is more effective than treatment with tablets to prevent stroke. In some patients a treatment called stenting where a wire mesh tube is inserted via an artery in the groin and opened up across the narrowing in the neck may be as effective as surgery. However, drug therapy has improved since the original trials of surgery. The trialists think medical therapy is now so effective that the benefits of removing the narrowing may not justify the risk of surgery or stenting in patients with a lower risk of stroke e.g. those who have had no symptoms for some months from the narrowing or never had symptoms. They propose a clinical trial to determine whether these patients should be managed by drug therapy alone or should still be referred for surgery or stenting. |
| Ethics approval(s) | National Research Ethics Service Committee – East of England, Cambridge Central, 19/10/2011, ref: 11/EE/0347 |
| Condition | Stroke |
| Intervention | Immediate endartorectomy and optimised medical therapy. All patients will have their medication adjusted to reach recommended levels for cholesterol and blood pressure, and receive advice about healthy lifestyle. Half the patients will be randomly allocated to have surgery or stenting as soon as possible, the other half will continue on medical treatment alone until such time, if ever, that revascularisation becomes clearly indicated. Patients will be seen regularly for several years to check their cholesterol and blood pressure remain on target and to record surgical complications and the occurrence of strokes or heart attacks. An interim safety analysis will be performed using MRI follow up to assess rates of new cerebral infarction and haemorrhage. |
| Intervention type | Mixed |
| Primary outcome measure | Any stroke at any time + non-stroke death within 30 days of endartorectomy |
| Secondary outcome measures | Added 06/05/2016: The long-term rates of the following outcomes: 1. Ipsilateral stroke, confirmed/probable TIA, MI or any hospitalisation for vascular disease during follow up 2. Disabling stroke during follow up 3. New cerebral infarction or parenchymal haemorrhage on follow up MRI 4. Increase in white-matter changes on follow up MRI 5. Revascularisation during follow-up 6. Stenosis progression (defined as recurrent stenosis of the randomised artery after revascularisation, or progression in severity of stenosis in a non-revascularised artery) 7. The combination of stenosis progression or revascularisation during follow-up 8. Functional status as assessed by comparison of modified Rankin scale scores 9. The cost-effectiveness of carotid endarterectomy with OMT compared to OMT alone 10. Cognitive impairment or dementia during follow up reported by the investigator and measured by the Montreal Cognitive Assessment (MoCA) 11. Decline in functional status as assessed by an increase in the modified Rankin score (mRS) 12. Health-related quality of life and economic costs Secondary analysis will also examine the risk factors for stroke, cognitive impairment and the other main outcome events during long term follow up (including the risks related to age, sex, symptoms, baseline brain imaging, centre and technique). In centres performing the relevant additional investigations, secondary analyses will examine the relationship between the main outcome events and baseline measures of plaque instability as determined by MR plaque imaging. |
| Overall study start date | 23/03/2012 |
| Overall study end date | 31/03/2025 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | UK Sample Size: 200 |
| Total final enrolment | 429 |
| Participant inclusion criteria | 1. Patients over 18 years of age with atherosclerotic carotid stenosis equivalent to at least 50% measured using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method 2. Patient is medically and neurologically stable and suitable for CEA or carotid artery stenting (CAS) 3. Patients with a carotid artery risk (CAR) score indicating a 5-year ipsilateral stroke risk of <20%. This may include patients with asymptomatic stenosis or symptomatic stenosis associated with features (e.g. delayed presentation) indicating intermediate or lower risk, confirmed by CAR Score <20% 4. Clinicians are uncertain about which treatment modality is best for the individual patient 5. Patient or appropriate representative is able and willing to give informed consent 6. Male and female participants |
| Participant exclusion criteria | 1. Patients (or their representatives) unwilling to have either treatment modality 2. Patients unwilling or unable to participate in follow up for whatever reason 3. Patients with a Rankin score greater than 3 for any reason. Such patients may be eligible for inclusion at such time as they improve to a Rankin score of 3 or less 4. Patients who are medically or neurologically unstable or have progressing neurological signs. Such patients may be eligible for inclusion at such time as they become stable 5. Patients in whom it is planned to carry out coronary artery bypass grafting or other major surgery within one month of carotid stenting or endarterectomy 6. Patients with a CAR Score >20% or other reason for believing the patient would get clear benefit from CEA or CAS 7. Patients not suitable for either surgery or stenting due to anatomical factors 8. Carotid stenosis caused by nonatherosclerotic disease e.g. dissection, fibromuscular disease or neck radiotherapy 9. Previous CEA or stenting in the randomised artery 10. Patients who are known to be pregnant 11. Patients who have a life expectancy of less than two years due to a preexisting condition e.g. cancer 12. Patients intolerant or allergic to all of the medications available for optimised modern medical therapy 13. Patients in clinical trials of medicinal products (CTIMPS) or who have been in a CTIMP within the last 4 months will not be enrolled 14. Patients in other trials (both stroke related and non stroke related) may be enrolled where this would not conflict with the treatments used in ECST2 or place undue additional burdens on the patient |
| Recruitment start date | 23/03/2012 |
| Recruitment end date | 31/10/2019 |
Locations
Countries of recruitment
- Canada
- England
- France
- Germany
- Italy
- Netherlands
- Scotland
- Switzerland
- United Kingdom
Study participating centres
WC1N 3BG
United Kingdom
United Kingdom
United Kingdom
United Kingdom
-
Germany
United Kingdom
United Kingdom
United Kingdom
Netherlands
United Kingdom
United Kingdom
Netherlands
United Kingdom
United Kingdom
United Kingdom
Switzerland
United Kingdom
United Kingdom
United Kingdom
Netherlands
-
Canada
-
France
-
Germany
-
Italy
-
Switzerland
-
Switzerland
-
Netherlands
-
Netherlands
-
Netherlands
KT16 0PZ
United Kingdom
M8 5RB
United Kingdom
Sponsor information
University/education
Institute of Neurology
Queen Square
London
WC1N 3BG
England
United Kingdom
| Website | http://www.ucl.ac.uk/ |
|---|---|
"ROR" |
https://ror.org/02jx3x895 |
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
Private sector organisation / Associations and societies (private and public)
- Location
- United Kingdom
Private sector organisation / Trusts, charities, foundations (both public and private)
- Alternative name(s)
- Schweizerischer Nationalfonds, Swiss National Science Foundation, Fonds National Suisse de la Recherche Scientifique, Fondo Nazionale Svizzero per la Ricerca Scientifica, Fonds National Suisse, Fondo Nazionale Svizzero, Schweizerische Nationalfonds, SNF, SNSF, FNS
- Location
- Switzerland
Results and Publications
| Intention to publish date | 31/12/2023 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Publication of the main results will be submitted to a high-impact peer reviewed journal within one year after completion of randomisation and planned follow up. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study will be available upon request from the chief investigator Prof. Martin Brown. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | 27/07/2022 | 28/07/2022 | Yes | No | |
| Interim results article | 2-year interim results | 20/04/2025 | 23/04/2025 | Yes | No |
Editorial Notes
23/04/2025: Publication reference added.
21/09/2023: The intention to publish date was changed from 31/03/2023 to 31/12/2023.
28/07/2022: Publication reference added.
09/06/2022: The overall trial end date has been changed from 31/03/2022 to 31/03/2025 and the plain English summary has been updated accordingly.
10/11/2020: The following changes were made to the trial record:
1. The funders Stroke Association UK, and the Swiss National Science Foundation were added.
2. The study contact was updated.
3. The recruitment end date was changed from 31/03/2022 to 31/10/2019. The trial steering committee decided stop randomisation in ECST-2 after recruiting sufficient patients to conduct both the planned brain imaging-based analysis of outcome events and a analysis of outcomes based on MR plaque imaging analysis. Recruitment was therefore stopped in October 2019 with a total of 429 patients recruited in the trial. Follow-up is planned to continue until at least October 2021.
4. The total final enrolment was added.
5. The trial participating centres Cumberland Infirmary and University Hospitals Coventry and Warwickshire were removed.
6. The trial participating centres Dalhousie University, Hospices Civiles de Lyon, University of Leipzig, Verona University Hospital, Kantonsspital St. Gallen, NSI-Lugano, Maastricht University Medical Centre, Radbound University Nijmegen Medical Centre, University Medical Center Utrecht, Ashford and St Peter’s Hospitals NHS Foundation Trust, Pennine Acute Hospitals NHS Trust were added.
7. The plain English summary was updated to reflect these changes.
05/06/2017: Publication and dissemination plan and IPD sharing statement added.
11/02/2016: Plain English summary added.
